Vitamin Market Outlook For 2008
This article was originally published in PharmAsia News
In 2007, vitamin products-calcium pantothenate, folic acid, vitamins A, B2, and C-experienced high price increase. Analysts attribute the hike to the monopoly enjoyed by major companies, as well as the inflated cost of raw materials. However, observers do not expect vitamin products to continue enjoying such strong growth in 2008; the temporary price spike was caused by increased costs in infrastructure, environmental management, raw materials and labor. Mostly, vitamin prices hover around cost, and more competitors entering the market will add to the depression. Last year's adjustment of export tax rebates have adversely impacted many sectors; the clamp-down on high-energy, high-polluting industries will further curtail the development of many companies, including those producing vitamins. (Click here for more - Chinese Language)
You may also be interested in...
Lawyer asks US FDA to require another trial before licensing Mesoblast’s stem cell therapy for children with SR-aGVHD; Incyte’s Jakafi is only product approved for the indication.
Hanmi licenses out GLP-1/glucagon receptor dual agonist for NASH to Merck, in a deal worth up to $870m, marking a positive turn for the Korean firm's pipeline after Janssen returned rights last year.
Nomolotus discontinued social media claims that its herbal supplement supports users’ immune systems during the COVID-19 pandemic and customers reviews referencing the virus after the National Advertising Division questioned the statements as misleading.